ASCO 2026

[Palex80]

Advertisement - Members don't see this ad

Let's gather some interesting ASCO abstracts from this year's meeting!

 

[drowsy12]

 

[drowsy12]

 

[TheWallnerus]

Pretty remarkable curve separation

I guess this means PCI for NSCLC could finally show significant benefit for certain subsets 😉

 

[Palex80]

I guess this means PCI for NSCLC could finally show significant benefit for certain subsets 😉

Exactly, those 3% ALK mutated ones kept screwing all the trials!

 

[RickyScott]

Any news on the prostate plenary that will show a benefit to second generation arb prior to surgery? (Proteus) sounds like it will really hurt us. Kind of like neoadjuvant in stage 3 nsclc.

 

[Gfunk6]

https://www.asco.org/abstracts-presentations/259084/abstract

ROADS is interesting and probably practice-changing, but I would not declare postop cavity SRS dead based on the ASCO abstract alone.

Randomized phase III trial in resected brain metastases, comparing intraoperative Cs-131 collagen tile brachytherapy/GammaTile versus standard postop SRT. The headline result is very strong: markedly lower surgical-bed recurrence with tiles, with no obvious major toxicity penalty, and an unexpectedly large OS difference.

The logic makes sense. The biggest weakness of postop cavity SRS is operational: delay after surgery, cavity evolution, contour uncertainty, missed or late treatment, and systemic therapy interruption. GammaTile solves a lot of that by treating immediately at resection, before the cavity changes and before the patient falls into the postoperative scheduling abyss.

That said, the OS delta is too large for me to swallow whole without seeing the manuscript. I’d want to look carefully at histology, systemic therapy balance, extracranial disease status, salvage patterns, and how many patients on the control arm actually received timely, high-quality postop SRT.

Bottom line: very strong local-control signal, real logistical advantage, and likely useful for selected large resected brain mets. But I want the full paper before pretending this invalidates well-executed postop cavity SRS.

 

[TheWallnerus]

https://www.asco.org/abstracts-presentations/259084/abstract

ROADS is interesting and probably practice-changing, but I would not declare postop cavity SRS dead based on the ASCO abstract alone.

Randomized phase III trial in resected brain metastases, comparing intraoperative Cs-131 collagen tile brachytherapy/GammaTile versus standard postop SRT. The headline result is very strong: markedly lower surgical-bed recurrence with tiles, with no obvious major toxicity penalty, and an unexpectedly large OS difference.

The logic makes sense. The biggest weakness of postop cavity SRS is operational: delay after surgery, cavity evolution, contour uncertainty, missed or late treatment, and systemic therapy interruption. GammaTile solves a lot of that by treating immediately at resection, before the cavity changes and before the patient falls into the postoperative scheduling abyss.

That said, the OS delta is too large for me to swallow whole without seeing the manuscript. I’d want to look carefully at histology, systemic therapy balance, extracranial disease status, salvage patterns, and how many patients on the control arm actually received timely, high-quality postop SRT.

Bottom line: very strong local-control signal, real logistical advantage, and likely useful for selected large resected brain mets. But I want the full paper before pretending this invalidates well-executed postop cavity SRS.

Even if the result is real, few currently practicing rad oncs will be able to justify doing this because brachy reimburses so poorly vs fSRS (technically and wRVU wise), not to mention the OR time suck away from clinic (especially if you’re not hospital based).